Document is current

Article History

Received: 8 March 2019

Accepted: 1 April 2019

First Online: 24 April 2019

Compliance with ethical standards

:

: Geoffrey I. Shapiro declares that he was on the advisory board at Almac, Angiex, Astex, Bayer, Bicycle Therapeutics, Cybrexa Therapeutics, Daiichi Sankyo, Fusion Pharmaceuticals, G1 Therapeutics, Ipsen, Lilly, Merck/EMD Serono, Pfizer, Roche, and Sierra Oncology; funding for an investigator-initiated clinical trial from Array and Pfizer; sponsored research agreements from Lilly, EMD Serono, Merck, and Sierra Oncology; support to the Dana-Farber Cancer Institute for this study from Genentech; travel from Bayer, Bicycle Therapeutics, G1 Therapeutics, Lilly, Pfizer, and Sierra Oncology; patent 9,872,874 issued for “Dosage regimen for sapacitabine and seliciclib” and provisional patent application 62/538,319 for “Compositions and methods for predicting response and resistance to CDK4/6 inhibition.” Patricia LoRusso declares that she was on the advisory board at Alexion, Ariad, GenMab, Glenmark, Menarini, Novartis, Genentech, CytomX, Omniox, Ignyta, and Takeda; data safety monitoring board at Agios, Halozyme, and FivePrime; imCORE alliance at Roche/Genentech; and consultant at SOTIO. Eunice Kwak declares that she is an employee of Novartis and former employee of Massachusetts General Hospital Cancer Center where this study was conducted. Susan Pandya declares that she is an employee of Agios and former employee of Beth Israel Deaconess Medical Center where this study was conducted. Charles M. Rudin declares that he was a consultant for AbbVie, Amgen, Ascentage, Astra Zeneca, Bicycle, BMS, Celgene, Daiichi Sankyo, Genentech/Roche, Ipsen, Loxo, Pharmamar, and scientific advisory board at Elucida and Harpoon. Carla Kurkjian declares that she has no conflict of interest. James M. Cleary declares research funding from Merck and Tesaro; consulting at Bristol Myers Squib; and travel funding from Bristol Myers Squib, Agios, and Roche. Mary Jo Pilat declares that she has no conflict of interest. Suzanne Jones declares that her institution received payment for services related to clinical trial from AbbVie, Acerta Pharma, Agios, Amgen, ARMO Biosciences, Array Biopharma, AstraZeneca, Blueprint Medicine, Boston Biomedical, Bristol Myers Squibb, CALGB, Celgene, Daiichi Sankyo, Eisai, EMD Serono, Genentech, Gilead Sciences, Imclone, Incyte, Ipsen Biopharma, Leap Therapeutics, Lilly, Macrogenics, MedImmune, Merck, Merrimack, Merus NV, Millennium, Novartis, Novocure, OncoMed Pharmaceuticals, Pfizer, Rgenix, Roche, Taiho Oncology, and Takeda Pharmaceuticals; and institution received payment for consulting services performed by Dr. Jones from Vertex, Novartis, Teva, Onyx, Clovis, and Janssen. Alex de Crespigny, Jill Fredrickson, Luna Musib, Yibing Yan, and Matthew Wongchenko declare that they are employees of Genentech, Inc., and are stockholders of Roche. Hsin-Ju Hsieh declares that she is an employee at MedImmune; former employment at Genentech, Inc., and stockholder of Roche. Mary R. Gates and Iris T. Chan declare that they are employees of Genentech, Inc. and are stockholders of Roche. Johanna Bendell declares that her institution received payment for services related to clinical trial from AbbVie, Acerta Pharma, Agios, Amgen, ARMO Biosciences, Array Biopharma, AstraZeneca, Blueprint Medicine, Boston Biomedical, Bristol Myers Squibb, CALGB, Celgene, Daiichi Sankyo, Eisai, EMD Serono, Genentech, Gilead Sciences, Imclone, Incyte, Ipsen Biopharma, Leap Therapeutics, Lilly, Macrogenics, MedImmune, Merck, Merrimack, Merus NV, Millennium, Novartis, Novocure, OncoMed Pharmaceuticals, Pfizer, Rgenix, Roche, Taiho Oncology, and Takeda Pharmaceuticals; institution received payment for consulting services performed by Dr. Bendell from Amgen, Arrys Therapeutics, BeiGene, Bristol Myers Squibb, Celgene, Cerulean, Continuum Clinical, Daiichi Sankyo, Evelo Biosciences, Five Prime Therapeutics, Forma Therapeutics, Genentech, Janssen, MedImmune, Merck, Merrimack, Moderna Therapeutics, Roche, Seattle Genetics, Taiho Oncology, Tanabe Research Laboratories, Tolero, and Translational Drug Development; Dr. Bendell received non-financial support including travel reimbursement and medical editing support from Genentech; and Dr. Bendell also received in-kind support for food and beverage from Genentech.

: This article contains studies with human participants performed by the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.